Verge is focused on developing therapeutics for serious genetic diseases using human genomics and machine learning.

Verge has created a proprietary all-in-human platform, featuring one of the field’s largest and most comprehensive databases of neurodegenerative patient genomic data. The company is led by experienced computational biologists and drug developers who are successfully advancing therapeutic programs in ALS and Parkinson’s disease toward the clinic and became on the of the first AI-focused therapeutic companies to begin human trials. In 2022 Verge signed a partnership agreement with Eli Lilly worth potentially $750M+. Fitz Gate invested in Verge’s Series A alongside Draper and Threshold Ventures. One year later Blackrock led the company’s $80M Series B with participation by Eli Lilly, Glaxo, Astra Zeneca and others.

Alice Zhang

Founder & CEO

Related News

March 7, 2024 in Portfolio News, Verge Genomics

Fitz Gate portfolio company Verge Genomics has received positive attention for its first-of-its-kind, cutting-edge design and technology

Biotech has long recognized the benefits of using digital endpoints in clinical trials. Putting it…
Read More
September 15, 2023 in Verge Genomics

Verge Genomics inks $882 million AI drug discovery pact with AstraZeneca Alexion

Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence (AI) and patient…
Read More
June 20, 2023 in Portfolio News, Verge Genomics

Fitz Gate Portfolio Company Verge Genomics announces completion of phase 1 testing for it’s ALS drug candidate

VRG50635 was safe and well tolerated in healthy adult volunteers after both single and repeated…
Read More